Pre-clinical studies revealed that SGLT2 inhibitors attenuate myocardial oxidative stress, fibrosis, and DCM by inhibiting NLRP3 inflammasome-mediated pyroptosis in diabetic mouse heart (57–59). This evidence concerns the gene SLC5A2 and familial dilated cardiomyopathy.